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Institute of Hepatology, London & Foundation for Liver Research, United KingdomThe report of the Lancet Commission [1] published in the Lancet
on November 27th 2014, makes for interesting reading. It was
entitled ‘‘Addressing the Crisis of Liver Disease in the UK: A blue-
print for obtaining excellence in healthcare for liver disease and
reducing premature mortality from the major lifestyle issues of
excess alcohol consumption, obesity and viral hepatitis’’. The
ﬁndings in the UK are also relevant to current concerns over liver
disease in Europe. An important milestone at the European policy
level is the launch in the European Parliament [2] last month, by
the European Association for the Study of the Liver (EASL), of the
‘Research Roadmap for Liver Disease’ (HEPAMAP). In 2013,
29 million people in the EU were documented as suffering from
a chronic liver condition and HEPAMAP identiﬁes opportunities
to signiﬁcantly reduce liver mortality and decrease the burden
of liver conditions in the EU by the end of 2020, with particular
emphasis on tackling alcohol- and obesity-related liver condi-
tions with evidence-based policy measures.
The recommendations of the Lancet report, with nearly two
hundred references, are based on the work of some ﬁfty experts
from a wide variety of disciplines. They reviewed in detail epi-
demiological and clinical data, including an important report
from the National Conﬁdential Enquiry into Patient Outcomes
and Death (NCEPOD) [3], of an audit carried out in hospitals
around the country on the care of adult liver patients admitted
to hospital. Major deﬁciencies in the available facilities and lack
of expertise in those caring for the patients were documented.
Only 2.9% of the patients had been seen by a consultant
Hepatologist on arrival. Care was judged to have been good in
less than half the cases and deaths were considered avoidable
in over 10%.
The statistics for the UK are horrifying. Liver disease stands
out as the one glaring exception to the vast improvement over
the past 30 years in health and life expectancy for chronic disor-
ders such as strokes, heart disease and many cancers. MortalityJournal of Hepatology 20
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Open access under CC BY-NC-ND license.rates have increased 400% since 1970 and in those under the
age of 65 years have risen almost ﬁve-fold (Fig. 1). Liver disease
currently constitutes the third commonest cause of premature
death in the UK and the rate is considerably higher than for other
countries in Europe. The UK overtook France, Italy and Spain in
terms of liver mortality some years ago and only Finland, where
the availability of alcohol, as in the UK, was liberalised, has seen a
similar upward trend in liver mortality [4].
Over 1 million hospital admissions a year are the result of
alcohol related conditions and both the number of admissions
and the increase in mortality closely parallels the rise in alcohol
consumption in the UK during recent decades [5,6].
Similarly, with 25% of the population now categorised as
obese, the numbers of patients being diagnosed with type II dia-
betes and other medical consequences of the metabolic syn-
drome including non-alcoholic fatty liver disease (NAFLD) are
staggering [7]. 10–15% of NAFLD patients have ongoing inﬂam-
mation and ﬁbrosis leading ﬁnally to cirrhosis and to primary
hepatocellular carcinoma. A substantial proportion of obese sub-
jects will also be drinking heavily, adding to the risk of develop-
ing hepatocellular carcinoma. Obesity and alcohol consumption
act synergistically in producing liver damage and obesity is
known to accelerate progression of liver diseases from other aeti-
ologies including hepatitis C and haemochromatosis. NAFLD is
now thought to be the cause of many instances of what was pre-
viously termed cryptogenic cirrhosis.
The number of chronically infected HCV and HBV subjects in
the country is another major disease burden. Annual deaths from
hepatitis C have almost quadrupled since 1996 and around 75% of
an estimated 160,000 infected cases in the country are still
unrecognised [8–10]. Similarly, for chronic hepatitis B infection,
the pool of silent infected subjects in the UK is increasing each
year as a result of immigration from countries with a high preva-
lence of infection. No testing for HBV or HCV infection at the time
of visa application is in place as in many countries around the
world [11] (Table 1).
The costs to the National Health Service are equally stagger-
ing, with estimates of £3.5 billion a year for alcohol health prob-
lems and £5.5 billion for the consequences of obesity [7]. Those
for obesity are almost certainly an underestimate as obesity is
such an important risk factor in a number of common cancers
including breast and colon, as shown in a recent cohort study
of 5.24 million UK adults [12]. Furthermore, it is the poorest
and most vulnerable in society, living in areas of highest social15 vol. 63 j 297–299
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Fig. 1. Percentage changes in standardised UK mortality rates (age 0–64)
normalised to 100% in 1980. Standardised Mortality Rate data for the UK was
downloaded from the World Health Organisation Health for All Database
(http://data.euro.who.int/hfadb/) and normalised to 100% in 1980. (Nick Sheron,
October 2013).
Table 1. Summary of four major problems identiﬁed by the Lancet
Commission.
1 Increased number of admissions and poor hospital care 
for acutely sick patients with liver disease
2 Rising burden of NAFLD, NASH, cirrhosis and primary 
hepatocellular carcinoma from high levels of obesity in 
the UK, and diabetes
3 Number of chronically infected HCV and HBV subjects 
currently not identified and being considered for 
treatment
4 Lack of knowledge in primary care and deficiencies in 
diagnostic facilities
Table 2. Summarising actions needed to address major issues of liver disease
care and prevention as recommended in the report of the Lancet Commission.
1 Improving services in District General Hospitals for 
acutely sick patients, linked with regional Specialist 
Centres
2 Reduction in overall alcohol consumption through 
Government action implementing minimum unit price 
policy and restrictions on advertising and promotions. 
Similar intervention to reduce sugar content of food and 
soft drinks 
3 Nationwide programme for eradication of HCV using new 
antiviral drugs and measures to reduce HBV infections 
through immigration
4 Additional training in liver disease and appointment of 
community hepatologists; use of AST/ALT ratio in triage 
and mobile Fibroscan as confirmatory test for early 
diagnosis 
Editorialdeprivation, who have the highest incidence of liver conditions,
making it a major health inequalities issue.
The seven sections of the report provide a comprehensive
account of liver disease in the UK. Each of the sections has
detailed recommendations fromwhich ten were selected as those
most likely to have the greatest impact on disease burden and
which were strongly endorsed for urgent action.
Section 1, in giving statistics on the extent of the problem and
the current deﬁciencies in hospital and primary care, recom-
mends strengthening detection of early liver disease in primary
care through positioning of liver disease within the ‘Big 5’ major
chronic diseases to maximise the impact of general interventions.
Section 2 provides a blueprint for improving hospital care
through enhanced 7-day acute liver services in DGHs and 30
regional specialist centres distributed equitably around the coun-
try. A national review of liver transplant services is recommended
to provide sufﬁcient capacity for the anticipated 50% increase in
availability of donor organs by 2020. Proposals for increasing
medical and nurse training in hepatology to enable the necessary
increase in stafﬁng levels in hospitals and primary care, are also
detailed (Table 2).
Section 3 deals with measures for scaling up national action
to reduce the country’s overall alcohol consumption including
implementation by Government of a Minimum Unit Price policy
for alcohol, along with restrictions on advertising and alcohol
promotions in supermarkets [13,14]. Legislative action on the
food industry to reduce sugar content in food and soft drinks
was considered essential. Based on results of modelling298 Journal of Hepatology 201techniques, eradication of HCV by 2030 using the new antiviral
drugs was considered to be a feasible proposition [8–10] but
was dependent on the scaling up of screening programmes to
identify the large numbers of currently undiagnosed infected
subjects. The introduction of universal infant vaccination against
HBV in accordance with the WHO policy was yet again recom-
mended. Section 4 reports on what is needed to obtain greater
engagement of primary care in the early detection and treat-
ment of liver disease including guidelines and deﬁned care bun-
dles. Addition of the AST/ALT ratio to the standard liver function
tests to facilitate triage of signiﬁcant liver disease and use of
conﬁrmatory liver elastography, were also recommended.
Section 5 on Paediatric Liver Disease, in stressing the value of
having three designated national centres in achieving excellent
outcomes for biliary atresia, emphasised the need for better
transitional care facilities for the increasing number of children
with liver disease, including liver transplant recipients surviving
to adulthood.
An economic analysis of the costs of liver disease to the NHS is
developed in section 6, with the potential savings obtainable
through preventative and better treatment measures, and the
ﬁnal section 7 looks at promoting better public understanding
of liver issues including the establishment of a web-based infor-
mation portal carrying data on standards of care and clinical
outcomes.
Following on from publication of the report, the editor of the
Lancet decided that work should continue through a Standing
Commission, with a follow-up report to be published in
November on progress with implementation of the recommenda-
tions. An additional working group on Diagnostic and Invasive
Radiological Services including surveillance for primary hepato-
cellular cancer, has been set up and important collaborations
put into place with Public Health England bringing together
nationwide activities on public health.Conﬂict of interest
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